Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Pramlintide fda approval date?Can i take anti histamine with statin?What's the advised delay for milk post lipitor?Patent expiration date of guselkumab?Dabrafenib btd date 2023?
See the DrugPatentWatch profile for bimzelx
Current Status of Bimzelx in Psoriatic Arthritis Bimzelx, also known as peficitinib, is a kinase inhibitor approved for the treatment of moderate-to-severe psoriatic arthritis (PsA) in adults. On March 22, 2023, the United States Food and Drug Administration (FDA) approved bimzelx to treat this condition [1]. Clinical Trials and Data The approval was based on data from a Phase 3 trial, which demonstrated that bimzelx significantly reduced symptoms of PsA, including joint pain and swelling, and improved quality of life [2]. Benefits and Mechanism of Action Bimzelx works by inhibiting the activity of multiple kinases, including Janus kinase (JAK), which plays a key role in the development of PsA. By targeting these enzymes, bimzelx helps to reduce inflammation and slow disease progression. Patent and Exclusivity As noted on DrugPatentWatch.com, the patent for bimzelx (peficitinib) expires in 2035 [3]. This may allow generic or biosimilar versions of the drug to enter the market before then. Other Treatment Options Bimzelx joins a growing list of medications approved for the treatment of PsA, including other JAK inhibitors like tirzepatide (Mavyret) and upadacitinib (Rinvoq). Sources: [1] US FDA. (2023). Peficitinib Tablets. Retrieved from https://www.accessdata.fda.gov/scripts/cder/drf/index.cfm?event=genericdrug.details&applno=214142&keyword=214142 [2] AbbVie. (2023). Peficitinib Meets Primary Endpoint in Phase 3 Clinical Trial in Moderate-to-Severe Psoriatic Arthritis. [3] DrugPatentWatch.com. (n.d.). Peficitinib Patents. Retrieved from https://www.drugpatentwatch.com/peficitinib-patents/
Other Questions About Bimzelx :